Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-16T17:22:40.139Z Has data issue: false hasContentIssue false

18 - Pharmacological immunosuppression

Published online by Cambridge University Press:  06 January 2010

Nicholas R. Banner
Affiliation:
Royal Brompton and Harefield NHS Trust, Imperial College of Science, Technology and Medicine, London
Julia M. Polak
Affiliation:
Imperial College of Science, Technology and Medicine, London
Magdi H. Yacoub
Affiliation:
University of London
Get access

Summary

Introduction

Pharmacological immunosuppression is required after all types of organ transplantation to prevent rejection of the allograft. Immunosuppressive drugs have a potential for serious toxicity. Due to the strength of the alloimmune response [1, 2], the drugs that are currently available cannot be used as single agents to prevent rejection without unacceptable toxicity. Current practice is therefore to use combinations of agents with complementary immunosuppressive actions but differing adverse effects to achieve synergistic immunosuppression with the lowest possible toxicity [3–5].

However, this approach does not overcome the other main problem associated with the use of these drugs, which is that their effect is not specific for the immune response to the allograft. Nonspecific immunosuppression increases the risk of both infection and certain types of malignancy in the transplant recipient [6, 7]. Although progress has been made through the introduction of potent immunosuppressive agents that affect predominantly those aspects of the immune response central to allograft rejection [8–10], the fundamental limitation of nonspecific immunosuppression remains.

The variety and complexity of clinical immunosuppression protocols has increased with the number of agents that are available and with the use of multiple-drug combinations; in addition, there are differing strategies for both the administration and the monitoring of individual drugs. The evidence base for treatment protocols in lung transplantation is limited. The number of lung transplantations that are performed in individual centres is usually too few to allow studies that can achieve a statistically robust conclusion. Many of the studies that have been published also have other methodological limitations that prevent unambiguous interpretation. Almost no large, multicentre, randomized clinical trials have been conducted in the field of lung transplantation.

Type
Chapter
Information
Lung Transplantation , pp. 205 - 242
Publisher: Cambridge University Press
Print publication year: 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×